[Cl:1][C:2]1[CH:3]=[C:4]([C:12]2([C:27]([F:30])([F:29])[F:28])[O:16][CH2:15][N:14]=[C:13]2[C:17]2[CH:25]=[CH:24][C:20]([C:21](O)=[O:22])=[C:19]([CH3:26])[CH:18]=2)[CH:5]=[C:6]([C:8]([F:11])([F:10])[F:9])[CH:7]=1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.[NH2:52][N:53]1[CH2:58][CH2:57][CH2:56][N:55]([CH2:59][C:60]([F:63])([F:62])[F:61])[C:54]1=[O:64]>C(Cl)Cl>[Cl:1][C:2]1[CH:3]=[C:4]([C:12]2([C:27]([F:28])([F:29])[F:30])[O:16][CH2:15][N:14]=[C:13]2[C:17]2[CH:25]=[CH:24][C:20]([C:21]([NH:52][N:53]3[CH2:58][CH2:57][CH2:56][N:55]([CH2:59][C:60]([F:61])([F:63])[F:62])[C:54]3=[O:64])=[O:22])=[C:19]([CH3:26])[CH:18]=2)[CH:5]=[C:6]([C:8]([F:9])([F:10])[F:11])[CH:7]=1Into a 50-mL round-bottom flask, was placed 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2,5-dihydro-1,3-oxazol-4-yl]-2-methylbenzoic acid (50 mg, 0.11 mmol, 1.00 equiv), dichloromethane (20 mL), EDCI (25 mg, 0.13 mmol, 1.20 equiv), HOBt (18 mg, 0.13 mmol, 1.20 equiv), TEA (30 mg, 0.30 mmol, 3.00 equiv), 1-amino-3-(2,2,2-trifluoroethyl)-1,3-diazinan-2-one (22 mg, 0.11 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 40 mL of DCM. The resulting mixture was washed with 3×20 mL of brine. The mixture was dried over anhydrous sodium sulfate. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:1). This resulted in 12 mg (17.2%) of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2,5-dihydro-1,3-oxazol-4-yl]-2-methyl-N-[2-oxo-3-(2,2,2-trifluoroethyl)-1,3-diazinan-1-yl]benzamide as a white solid. (ES, m/z): 631 [M+H]+ 1H-NMR (CDCl3, ppm): 7.82 (s, 1H), 7.76-7.73 (m, 2H), 7.69 (s, 1H), 7.61-7.50 (m, 3H), 4.14 (d, J=18.6 Hz, 1H), 4.07-3.98 (m, 2H), 3.80-3.69 (m, 3H), 3.58-3.52 (m, 2H), 2.51 (s, 3H), 2.25-2.17 (m, 2H).
読み込み中…